Stock Price Quote

SHILPA MEDICARE LTD.

NSE : SHILPAMEDBSE : 530549ISIN CODE : INE790G01031Industry : Pharmaceuticals & DrugsHouse : Private
BSE808.65-20.7 (-2.5 %)
PREV CLOSE ( ) 829.35
OPEN PRICE ( ) 845.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 19463
TODAY'S LOW / HIGH ( )797.00 845.95
52 WK LOW / HIGH ( )296.45 853.75
NSE810.15-20.2 (-2.43 %)
PREV CLOSE( ) 830.35
OPEN PRICE ( ) 830.35
BID PRICE (QTY) 810.15 (785)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 293297
TODAY'S LOW / HIGH( ) 796.45 832.30
52 WK LOW / HIGH ( )296.8 854.1
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987
Management Info
Omprakash Inani - Chairman Vishnukant Bhutada - Managing Director
Registered Office

Address Shilpa House,#12-6-214/ A1,Hyderabad Road,
Raichur,
Karnataka-584135

Phone 08532-238704

Email info@vbshilpa.com

Website www.vbshilpa.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

27Aug Shilpa Medicare secures USFDA’s approv
Shilpa Medicare has received the approval for its second NDA (505(b)(2))..
27Aug Shilpa Medicare zooms on securing USFD
Shilpa Medicare is currently trading at Rs. 760.75, up by 28.15 points o..
26Aug Shilpa Medicare completes phase-3 clin
Shilpa Medicare has successfully completed phase-3 clinical studies of i..
26Aug Shilpa Medicare informs about disclosu
Shilpa Medicare has informed that the company has successfully completed..
26Aug Shilpa Medicare soars on completing ph
Shilpa Medicare is currently trading at Rs. 729.95, up by 32.70 points o..

Financials

in Millions
QTR Jun 24 ANNUAL 24
Net Profit283.5269.37
Gross Profit 406.93 380.89
Operating Profit 554.041154.08
Net Sales 961.193097.87

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  29947.90 (1.03%)
M.Cap ( in Cr)63637.20
Neuland Laboratories (BSE)
peergroup  12900.55 (0.83%)
M.Cap ( in Cr)16551.26
RPG Life Sciences (BSE)
peergroup  2318.00 (3.60%)
M.Cap ( in Cr)3833.74
SMS Lifesciences (BSE)
peergroup  1664.65 (5.00%)
M.Cap ( in Cr)503.27
Mercury Laboratories (BSE)
peergroup  1092.00 (6.02%)
M.Cap ( in Cr)131.04

Shareholding Pattern

MUTUAL FUNDS/UTI 5.03%
PROMOTERS 44.39%
NON-INSTITUTION 38.92%
FI/BANKS/INSURANCE 1.25%
GOVERNMENT 0%
FII 0%

About Shilpa Medicare Ltd.

Shilpa Medicare Ltd. was incorporated in the year 1987. Its today's share price is 808.65. Its current market capitalisation stands at Rs 7907.86 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3097.87 Cr and Total Income of Rs.4031.25 Cr. The company's management includes Kalakota Sharath Reddy, Ritu Tiwary, Anita Bandyopadhyay, Kamal K Sharma, Arvind Vasudeva, Hetal Madhukant Gandhi, Vishnukant Bhutada, Omprakash Inani.

It is listed on the BSE with a BSE Code of 530549 , NSE with an NSE Symbol of SHILPAMED and ISIN of INE790G01031. It's Registered office is at Shilpa House,#12-6-214/ A1,Hyderabad RoadRaichur-584135, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bohara Bhandari Bung & Associates, Bohara Bhandari Bung & Associates LLP, Brahmayya & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.